Your session is about to expire
← Back to Search
Behavioural Intervention
eXciteOSA for Sleep Apnea (OREM Trial)
N/A
Waitlist Available
Research Sponsored by Signifier Medical Technologies
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up six weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing the eXciteOSA device, which helps people with mild sleep apnea. The device sends gentle electrical pulses to the tongue muscles to keep the airway open during sleep. The study will compare the effects of using this device versus no treatment over several weeks. The eXciteOSA device uses electrical stimulation to tone the tongue muscles, a method shown to improve sleep quality.
Eligible Conditions
- Sleep Apnea
- Obstructive Sleep Apnea
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ six weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~six weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Respiratory event index
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: TherapyExperimental Treatment1 Intervention
Neuromuscular electrical stimulation
Group II: No TherapyActive Control1 Intervention
Under the care of the referring physician, with no therapy applied
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
eXciteOSA
2022
N/A
~110
Find a Location
Who is running the clinical trial?
Signifier Medical TechnologiesLead Sponsor
3 Previous Clinical Trials
377 Total Patients Enrolled
Jessie P Bakker, PhDStudy DirectorSignifier Medical Technologies
2 Previous Clinical Trials
262 Total Patients Enrolled
Yasser ZayniStudy DirectorSignifier Medical Technologies
2 Previous Clinical Trials
262 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger